aldosterone and Left Ventricular Dysfunction studies

Research Excerpts

Excerpt	Relevance	Reference
"In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity."	9.24	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017)
" In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation."	7.72	[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003)
"Furosemide activates the renin-angiotensin-aldosterone system in patients with congestive heart failure (CHF)."	7.72	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004)
" The purpose of this study was to assess the relationship between levels of serum uric acid, activity of the renin-angiotensin-aldosterone system and TNF-alpha in heart failure patients with respect to the extent of left ventricular dysfunction."	7.71	Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002)
"Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months."	6.73	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007)
" All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12."	6.68	The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995)
"Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction."	6.42	Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	5.91	Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. ( Al-Hashedi, EM; Juvenal, H; Mohammed, AA; Yu, J; Zhao, X, 2023)
"Enalapril treatment in the chronic model, however, protected against cardiac dysfunction and cardiomyocyte atrophy and was associated with increased activation of the PI3K/AKT/mTOR pathway along with normal levels of CTGF."	5.48	Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. ( Basquin, D; Hullin, R; Maillard, M; Martin, D; Métrich, M; Regamey, J; Sarre, A, 2018)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	5.42	Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. ( Catena, C; Kraigher-Krainer, E; Pieske, B; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, N, 2015)
"Aldosterone plays a detrimental role in the pathology of chronic heart failure."	5.35	Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats. ( Bitsch, N; Essen, Hv; Hermans, JJ; Minnaard-Huiban, M; Smits, JF, 2008)
"Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure."	5.32	Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003)
"In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity."	5.24	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017)
"This was a double-blind, randomized comparison of isosorbide-5-mononitrate (IS-5-MN), 60 mg given orally, once daily for 11 months to patients (n = 47) with left ventricular (LV) dysfunction following acute myocardial infarction (AMI)."	5.12	Neurohumoral changes in patients with left ventricular dysfunction following acute myocardial infarction and the effect of nitrate therapy: a randomized, double-blind, placebo-controlled long-term study. ( Ohlin, H; Roijer, A; Thilen, U; Tingberg, E, 2006)
"The effect of torasemide and furosemide therapy was compared in 50 patients who had chronic heart failure and symptoms [NYHA class II-III] despite long-term therapy with both low-dose furosemide and angiotensin-converting enzyme inhibitors."	5.10	Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. ( Akutagawa, O; Fukuda, M; Hayashi, T; Honda, K; Okamoto, M; Sasaki, T; Yamato, M, 2003)
" We analysed the effects of early chronic VPI (50 mg/kg/day Omapatrilat) on cardiac remodelling and neurohumoral function during the progression of rapid ventricular pacing-induced heart failure in rabbits (early left ventricular dysfunction [ELVD]: 10 days at 330 bpm, CHF: further 10 days at 360 bpm)."	3.78	Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. ( Birner, C; Bratfisch, M; Dietl, A; Götz, T; Luchner, A; Riegger, GA; Schweda, F; Ulucan, C, 2012)
"Furosemide activates the renin-angiotensin-aldosterone system in patients with congestive heart failure (CHF)."	3.72	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004)
" In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation."	3.72	[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003)
" The purpose of this study was to assess the relationship between levels of serum uric acid, activity of the renin-angiotensin-aldosterone system and TNF-alpha in heart failure patients with respect to the extent of left ventricular dysfunction."	3.71	Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002)
"We assessed the relations among polymorphism of the angiotensin-converting enzyme gene, angiotensinogen M235T (AGT) gene, and angiotensin type I receptor A1166C gene with left ventricular systolic function, left and right ventricular diastolic function, serum angiotensin-converting enzyme, plasma aldosterone and atrial natriuretic peptide levels at presentation, and clinical outcome at 1 year (survival, hospital admissions) in a cohort of Chinese patients with typical systolic heart failure (n = 82)."	3.70	Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. ( Arumanayagam, M; Sanderson, JE; Shum, IO; Wei, S; Woo, KS; Young, RP; Yu, CM, 1999)
"Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months."	2.73	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007)
"Primary aldosteronism (PA) is a common cause of secondary hypertension and is associated with worse cardiovascular outcomes."	2.72	Left ventricular remodeling and dysfunction in primary aldosteronism. ( Chang, YY; Chen, ZW; Hung, CS; Lin, YH; Pan, CT; Tsai, CH; Wu, VC, 2021)
" All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12."	2.68	The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995)
"Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction."	2.42	Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	1.91	Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. ( Al-Hashedi, EM; Juvenal, H; Mohammed, AA; Yu, J; Zhao, X, 2023)
"Background Primary aldosteronism can cause cardiac dysfunction, including left ventricular hypertrophy, left ventricular diastolic dysfunction, and left atrial enlargement."	1.72	Comparison of Echocardiographic Changes Between Surgery and Medication Treatment in Patients With Primary Aldosteronism. ( Hoshino, Y; Inoue, K; Nakai, K; Nishikawa, T; Ono, M; Osada, J; Saito, J; Tsurutani, Y; Ueda, T; Yumoto, K, 2022)
"Primary aldosteronism (PA) may cause myocardial injury."	1.51	Speckle-Tracking Echocardiographic Layer-Specific Strain Analysis on Subclinical Left Ventricular Dysfunction in Patients With Primary Aldosteronism. ( Chen, X; Chen, Y; Li, Y; Shao, S; Wang, D; Wang, JG; Xu, JZ; Xu, TY; Zhang, W; Zhu, LM, 2019)
"Enalapril treatment in the chronic model, however, protected against cardiac dysfunction and cardiomyocyte atrophy and was associated with increased activation of the PI3K/AKT/mTOR pathway along with normal levels of CTGF."	1.48	Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. ( Basquin, D; Hullin, R; Maillard, M; Martin, D; Métrich, M; Regamey, J; Sarre, A, 2018)
"Primary aldosteronism is associated with a higher incidence of left ventricular (LV) hypertrophy and diastolic dysfunction than essential hypertension."	1.48	Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. ( Chang, YY; Chen, CW; Chen, ZW; Huang, KC; Hung, CS; Lee, JK; Liao, CW; Lin, LC; Lin, YH; Wu, VC, 2018)
"Primary aldosteronism is characterized by excess aldosterone (ALDO) secretion independent of the renin-angiotensin system and accounts for approximately 10% of hypertension cases."	1.46	Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats. ( Ball, JP; Hall, ME; Kc, R; Marañon, RO; Reckelhoff, JF; Romero, DG; Syed, M; Yanes Cardozo, LL, 2017)
"Primary aldosteronism (PA) causes excess left ventricular (LV) hypertrophy and diastolic dysfunction; whether this occurs also in secondary aldosteronism (SA) without hypertension is unknown."	1.43	Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study. ( Angeli, P; Cesari, M; Letizia, C; Rosi, S; Rossi, GP; Sciomer, S, 2016)
"HFpEF mice developed hypertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriuretic peptide expression."	1.43	Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. ( Aprahamian, T; Fuster, JJ; Hulsmans, M; Li, S; Nahrendorf, M; Sam, F; Scherer, PE; Valero-Muñoz, M; Wilson, RM, 2016)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	1.42	Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. ( Catena, C; Kraigher-Krainer, E; Pieske, B; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, N, 2015)
"In patients with sick sinus syndrome, DDD pacing mode can induce neuroendocrine system activation, and left ventricular dysfunction and dyssynchrony."	1.39	Neuroendocrine and haemodynamic changes in single-lead atrial pacing and dual-chamber pacing modes. ( Fu, NK; Lu, FM; Wu, DY; Xu, J; Zhang, YY, 2013)
"Hypertension was less marked in IFNγKO-aldosterone mice than in WT-aldosterone mice (127 ± 5 vs."	1.38	Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. ( Baid, S; Garcia, AG; Heo, J; Murthy, NR; Ouchi, N; Sam, F; Wilson, RM, 2012)
"In patients with dilated cardiomyopathy (DCM) abnormal myocardial blood flow (MBF) has been associated with coronary microvascular dysfunction."	1.36	Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy. ( Cabiati, M; Caselli, C; Del Ry, S; Giannessi, D; Iervasi, A; Maltinti, M; Mazzone, AM; Neglia, D; Prontera, C, 2010)
"Aldosterone plays a detrimental role in the pathology of chronic heart failure."	1.35	Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats. ( Bitsch, N; Essen, Hv; Hermans, JJ; Minnaard-Huiban, M; Smits, JF, 2008)
"Metabolic syndrome is a highly predisposing condition for cardiovascular disease and could be a cause of excess salt-induced organ damage."	1.35	Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T, 2008)
"Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure."	1.32	Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003)

Research

Studies (74)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

EFFICACY: Freedom From Congestion

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (10.81)	18.2507
2000's	35 (47.30)	29.6817
2010's	26 (35.14)	24.3611
2020's	5 (6.76)	2.80

Authors	Studies
Ueda, T	1
Tsurutani, Y	1
Osada, J	1
Inoue, K	1
Hoshino, Y	1
Ono, M	1
Nakai, K	1
Saito, J	1
Yumoto, K	1
Nishikawa, T	1
Al-Hashedi, EM	1
Zhao, X	1
Mohammed, AA	1
Juvenal, H	1
Yu, J	1
Sudani, HA	1
Shah, S	1
Lo, KB	1
Essa, H	1
Wattoo, A	1
Angelim, L	1
Brousas, S	1
Whybrow-Huppatz, I	1
Vellanki, S	1
Sankaranarayanan, R	1
Rangaswami, J	1
Karwacka, I	1
Kmieć, P	1
Kaniuka-Jakubowska, S	1
Pisowodzka, I	1
Fijałkowski, M	1
Sworczak, K	1
Tsai, CH	1
Pan, CT	1
Chang, YY	3
Chen, ZW	2
Wu, VC	3
Hung, CS	3
Lin, YH	3
Ball, JP	1
Syed, M	1
Marañon, RO	1
Hall, ME	1
Kc, R	1
Reckelhoff, JF	1
Yanes Cardozo, LL	1
Romero, DG	1
Huang, KC	1
Lee, JK	2
Lin, LC	1
Chen, CW	1
Liao, CW	1
Hullin, R	1
Métrich, M	1
Sarre, A	1
Basquin, D	1
Maillard, M	1
Regamey, J	1
Martin, D	1
Wang, D	1
Xu, JZ	1
Chen, X	1
Chen, Y	1
Shao, S	1
Zhang, W	1
Zhu, LM	1
Xu, TY	1
Li, Y	1
Wang, JG	1
Gregori, M	2
Tocci, G	2
Marra, A	1
Pignatelli, G	1
Santolamazza, C	1
Befani, A	2
Ciavarella, GM	2
Ferrucci, A	2
Paneni, F	2
Zhang, YY	1
Wu, DY	1
Fu, NK	1
Lu, FM	1
Xu, J	1
Lee, HH	1
Wu, XM	1
Wang, SM	1
Liao, MT	1
Chen, YH	1
Wu, KD	1
Catena, C	1
Verheyen, N	1
Pilz, S	1
Kraigher-Krainer, E	1
Tomaschitz, A	1
Sechi, LA	1
Pieske, B	1
Rossi, GP	3
Cesari, M	2
Valero-Muñoz, M	1
Li, S	1
Wilson, RM	2
Hulsmans, M	1
Aprahamian, T	1
Fuster, JJ	1
Nahrendorf, M	1
Scherer, PE	1
Sam, F	2
Letizia, C	1
Angeli, P	1
Sciomer, S	1
Rosi, S	1
Xanthakis, V	1
Enserro, DM	1
Larson, MG	1
Wollert, KC	1
Januzzi, JL	1
Levy, D	1
Aragam, J	1
Benjamin, EJ	1
Cheng, S	1
Wang, TJ	1
Mitchell, GF	1
Vasan, RS	1
Olivier, A	1
Pitt, B	5
Girerd, N	1
Lamiral, Z	1
Machu, JL	1
McMurray, JJV	1
Swedberg, K	1
van Veldhuisen, DJ	3
Collier, TJ	1
Pocock, SJ	1
Rossignol, P	1
Zannad, F	1
Pizard, A	1
Matsui, H	1
Ando, K	1
Kawarazaki, H	1
Nagae, A	1
Fujita, M	1
Shimosawa, T	1
Nagase, M	1
Fujita, T	1
Huang, BS	2
White, RA	2
Ahmad, M	2
Tan, J	1
Jeng, AY	1
Leenen, FH	2
Minnaard-Huiban, M	1
Hermans, JJ	1
Essen, Hv	1
Bitsch, N	1
Smits, JF	1
Kurita, T	1
Onishi, K	1
Dohi, K	1
Takamura, T	1
Fujimoto, N	1
Tanigawa, T	1
Imanaka-Yoshida, K	1
Wada, H	1
Nobori, T	1
Ito, M	1
Messaoudi, S	1
Milliez, P	1
Samuel, JL	1
Delcayre, C	1
Harada, K	1
Izawa, H	1
Nishizawa, T	1
Hirashiki, A	1
Murase, Y	1
Kobayashi, M	1
Isobe, S	1
Cheng, XW	1
Noda, A	1
Nagata, K	1
Yokota, M	1
Murohara, T	1
Shafiq, MM	1
Miller, AB	1
Del Ry, S	1
Giannessi, D	1
Maltinti, M	1
Cabiati, M	1
Prontera, C	1
Iervasi, A	1
Caselli, C	1
Mazzone, AM	1
Neglia, D	1
Brubaker, PH	1
Moore, JB	1
Stewart, KP	1
Wesley, DJ	1
Kitzman, DW	2
Yoshida, C	1
Goda, A	1
Naito, Y	1
Nakaboh, A	1
Matsumoto, M	1
Otsuka, M	1
Ohyanagi, M	1
Hirotani, S	1
Lee-Kawabata, M	1
Tsujino, T	1
Masuyama, T	1
Busseuil, D	1
Shi, Y	1
Mecteau, M	1
Brand, G	1
Gillis, MA	1
Thorin, E	1
Asselin, C	1
Roméo, P	1
Leung, TK	1
Latour, JG	1
Des Rosiers, C	1
Bouly, M	1
Rhéaume, E	1
Tardif, JC	1
Weir, RA	1
Tsorlalis, IK	1
Steedman, T	1
Dargie, HJ	1
Fraser, R	1
McMurray, JJ	1
Connell, JM	1
Ohtani, K	1
Usui, S	1
Kaneko, S	1
Takashima, S	1
Kitano, K	1
Yamamoto, K	1
Okajima, M	1
Furusho, H	1
Takamura, M	1
Butler, J	1
Ezekowitz, JA	1
Collins, SP	1
Givertz, MM	1
Teerlink, JR	1
Walsh, MN	1
Albert, NM	1
Westlake Canary, CA	1
Carson, PE	1
Colvin-Adams, M	1
Fang, JC	1
Hernandez, AF	1
Hershberger, RE	1
Katz, SD	1
Rogers, JG	1
Spertus, JA	1
Stevenson, WG	1
Sweitzer, NK	1
Tang, WH	1
Stough, WG	1
Starling, RC	1
Raizada, V	1
Hillerson, D	1
Amaram, JS	1
Skipper, B	1
Galuppo, P	1
Bauersachs, J	1
Garcia, AG	1
Heo, J	1
Murthy, NR	1
Baid, S	1
Ouchi, N	1
Birner, C	1
Ulucan, C	1
Bratfisch, M	1
Götz, T	1
Dietl, A	1
Schweda, F	1
Riegger, GA	1
Luchner, A	1
Marc, Y	1
Llorens-Cortes, C	1
Olexa, P	1
Olexová, M	1
Gonsorcík, J	1
Tkác, I	1
Kisel'ová, J	1
Olejníková, M	1
Shinohara, H	1
Fukuda, N	1
Soeki, T	1
Sakabe, K	1
Onose, Y	1
Tamura, Y	1
Albåge, A	1
Kennebäck, G	1
van der Linden, J	1
Berglund, H	1
Jessup, M	1
Yamato, M	1
Sasaki, T	1
Honda, K	1
Fukuda, M	1
Akutagawa, O	1
Okamoto, M	1
Hayashi, T	1
Qin, W	1
Rudolph, AE	1
Bond, BR	1
Rocha, R	1
Blomme, EA	1
Goellner, JJ	1
Funder, JW	1
McMahon, EG	1
Domanski, M	1
Norman, J	1
Haigney, M	1
Hanlon, S	1
Peyster, E	1
Catuzzo, B	1
Ciancamerla, F	1
Bobbio, M	1
Longo, M	1
Trevi, GP	1
Kolloch, R	1
Offers, E	1
Ghali, JK	1
McCurley, JM	1
Hanlon, SU	1
Wei, SK	1
Wedam, EF	1
Michalski, M	1
Haigney, MC	1
Weber, KT	1
Mizuno, Y	2
Yasue, H	2
Yoshimura, M	2
Harada, E	2
Fujii, H	2
Nakamura, S	2
Yamamoto, N	2
Ogawa, H	2
Nakao, K	2
Struthers, AD	1
De Feo, S	1
Franceschini, L	1
Brighetti, G	1
Cicoira, M	1
Zanolla, L	1
Rossi, A	1
Golia, G	1
Zardini, P	1
Tingberg, E	1
Roijer, A	1
Thilen, U	1
Ohlin, H	1
Boccanelli, A	1
Cacciatore, G	1
Mureddu, GF	1
de Simone, G	1
Clemenza, F	1
De Maria, R	1
Di Lenarda, A	1
Gavazzi, A	1
Latini, R	1
Masson, S	1
Porcu, M	1
Vanasia, M	1
Gonzini, L	1
Maggioni, AP	1
Choi, EY	1
Ha, JW	1
Yoon, SJ	1
Shim, CY	1
Seo, HS	1
Park, S	1
Ko, YG	1
Kang, SM	1
Choi, D	1
Rim, SJ	1
Jang, Y	1
Chung, N	1
Groban, L	1
Yamaleyeva, LM	1
Westwood, BM	1
Houle, TT	1
Lin, M	1
Chappell, MC	1
Reed, S	1
Greene, P	1
Ryan, T	1
Cerimele, B	1
Schwertschlag, U	1
Weinberger, M	1
Voelker, J	1
Stevens, TL	1
Burnett, JC	1
Kinoshita, M	1
Matsuda, Y	1
Redfield, MM	1
de Groote, P	1
Millaire, A	1
Racadot, A	1
Decoulx, E	1
Ducloux, G	1
Lerch, R	1
Montessuit, C	1
Zhuang, H	1
Yu, G	1
Li, J	1
He, J	1
Sacchetto, A	1
Pavan, E	1
Scognamiglio, R	1
Pietra, M	1
Pessina, AC	1
Lainchbury, JG	1
Richards, AM	2
Nicholls, MG	2
Espiner, EA	2
Yandle, TG	1
Sanderson, JE	1
Yu, CM	1
Young, RP	1
Shum, IO	1
Wei, S	1
Arumanayagam, M	1
Woo, KS	1
Rademaker, MT	1
Cameron, VA	1
Charles, CJ	1
Pemberton, CJ	1
Hillege, HL	1
Girbes, AR	1
de Kam, PJ	1
Boomsma, F	2
de Zeeuw, D	1
Charlesworth, A	1
Hampton, JR	1
Groenning, BA	1
Nilsson, JC	1
Sondergaard, L	1
Kjaer, A	1
Larsson, HB	1
Hildebrandt, PR	1
Andersen, UB	1
Steensgaard-Hansen, F	1
Rokkedal, J	1
Ibsen, H	1
Dige-Petersen, H	1
Nakayama, M	1
Sakamoto, T	1
Ito, T	1
Shimasaki, Y	1
Saito, Y	1
van den Berg, MP	1
Tjeerdsma, G	1
Jan de Kam, P	1
Crijns, HJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Exercise Conditioning in Elderly Patients With Heart Failure[NCT01113840]		201 participants (Actual)	Interventional	1993-07-31	Completed
The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study[NCT00132093]	Phase 4	100 participants	Interventional	2005-04-30	Completed
[NCT00000516]	Phase 3	0 participants	Interventional	1985-07-31	Completed
Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)[NCT01474200]		224 participants (Actual)	Interventional	2012-01-31	Terminated (stopped due to Closed due to patient recruitment challenges. No interim analyses were completed; study closure was not related to any concerns about safety or futility.)
Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure[NCT00403910]	Phase 3	500 participants	Interventional	2002-09-30	Completed
Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure[NCT02133105]	Phase 3	33 participants (Actual)	Interventional	2014-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Defined as jugular venous distention of < or equal to 8 cm, with no orthopnea, and with trace peripheral edema or no edema at hospital discharge (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Net Fluid Removed During the Index Hospitalization

Intervention	Participants (Number)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	40
IV Loop Diuretics (LD)	46

AQ-Fluid removed by AQ plus urine voided minus fluid intake versus urine voided minus fluid intake with the IV diuretics. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Time to Freedom From Congestion

Intervention	mL (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	12921
IV Loop Diuretics (LD)	8907

Time from hospital admission to time patient is free of congestion in the hospital. Freedom from congestion is defined as jugular venous distention of < or equal to 8 cm, with no orthopnea and with trace peripheral edema or no edema. Measurement taken every 24 hours after treatment initiation. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Total Fluid Removed During the Index Hospitalization

Intervention	Days (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	5.28
IV Loop Diuretics (LD)	3.86

AQ-Fluid removed by AQ plus urine voided versus urine voided when treated with IV diuretics (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Total Weight Loss During the Index Hospitalization

Intervention	mL (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	18700
IV Loop Diuretics (LD)	14043

Weight at hospital discharge minus weight at hospital admission. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days

EFFICACY: Weight Loss at 72 Hours After Initiation of Treatment

Intervention	lbs (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	-17.12
IV Loop Diuretics (LD)	-16.21

Weight at 72 hours after treatment initiation minus weight at treatment initiation. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: 72 hours after treatment initiation

Length of Stay (LOS) During the Index Hospitalization

Intervention	lbs (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	-10.69
IV Loop Diuretics (LD)	-10.30

Number of days patient is in hospital for HF treatment. (NCT01474200)
Timeframe: Index hospitalization admission to index hospitalization discharge

Mortality Rates Within Index Hospitalization or Within 90 Days After Hospital Discharge.

Intervention	Days (Mean)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	8.49
IV Loop Diuretics (LD)	7.19

Death due to any cause within index hospitalization and 90 days following hospital discharge. (NCT01474200)
Timeframe: Time from randomization to 90 days post-hospital discharge

Time to First Heart Failure (HF) Event

Intervention	Percentage of Participants (Number)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	15.45
IV Loop Diuretics (LD)	12.61

"Time to first HF event within 90 days after discharge from index HF hospitalization. HF events are defined as~HF rehospitalization or~unscheduled outpatient or emergency room treatment with IV loop diuretics or~unscheduled outpatient Aquapheresis treatment" (NCT01474200)
Timeframe: 90 days after discharge from index HF hospitalization.

CLINICAL: All Cause Rehospitalization Rates at 30 and 90 Days

Intervention	Days (Median)
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	62
IV Loop Diuretics (LD)	34

Any cause that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Global Clinical Score at 30 and 90 Days After Discharge

Intervention	Rehospitalizations/100 Pt-Days at Risk (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	0.899	1.109
IV Loop Diuretics (LD)	1.278	1.237

KCCQ Questionnaire analysis based on patient's self-assessment of how they feel at various intervals compared to how they felt prior to index treatment. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge

CLINICAL: Total Number of Cardiovascular (CV) Rehospitalizations at 30 and 90 Days After Discharge

Intervention	Scores on a Scale (Mean)
	Baseline	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	28.26	54.78	57.21
IV Loop Diuretics (LD)	31.83	53.08	60.56

CV symptoms that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Days for Cardiovascular (CV) Rehospitalizations at 30 and 90 Days After Discharge

Intervention	Rehospitalizations (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	17	46
IV Loop Diuretics (LD)	33	66

The total number of days spent in the hospital due to CV related events at 30 days and 90 days from hospital discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Days Rehospitalized for Heart Failure (HF) at 30 and 90 Days After Discharge

Intervention	Days (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	88	377
IV Loop Diuretics (LD)	207	554

Days rehospitalized for HF symptoms requiring hospital, emergency room or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Emergency Department (ED) or Unscheduled Office Visits at 30 and 90 Days After Discharge

Intervention	Days (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	68	338
IV Loop Diuretics (LD)	172	460

Number of visits for HF symptoms requiring ED or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

CLINICAL: Total Number of Heart Failure (HF) Rehospitalizations at 30 and 90 Days After Discharge

Intervention	Visits (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	4	7
IV Loop Diuretics (LD)	5	8

Number of different times patient was admitted to hospital for HF symptoms within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge

Days Alive and Out of Hospital at 30 and 90 Days After Discharge

Intervention	Rehospitalizations (Number)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	11	36
IV Loop Diuretics (LD)	24	52

Number of days patients were alive and out of the hospital at 30 and 90 days after discharge. (NCT01474200)
Timeframe: Within 30 and 90 days after hospital discharge

EFFICACY: Changes in B-type Natriuretic Peptide (BNP) Levels Over Time

Intervention	Days (Mean)
	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	27.29	62
IV Loop Diuretics (LD)	26.46	61.38

Change in BNP levels over time at 72 hours, discharge, and 90 days after discharge. (NCT01474200)
Timeframe: Baseline and at 72 hours from baseline, hospital discharge and at 90 days after hospital discharge

Quality of Life Assessed Using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 30, 60 and 90 Days After Discharge

Intervention	pg/mL (Mean)
	Baseline	72 hours from baseline	Discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	814.0	-169.8	-250.2	-159.9
IV Loop Diuretics (LD)	904.1	-120.5	-219.1	-201.3

Questionnaire assessed patients quality of life prior to index treatment versus timeframes following hospital discharge. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge

SAFETY: Changes in Renal Function (Blood Urea Nitrogen) After Treatment up to 90 Days After Randomization

Intervention	Scores on a Scale (Mean)
	Baseline	30 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	25.39	52.06	59.72
IV Loop Diuretics (LD)	28.64	49.36	58.50

Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization

SAFETY: Changes in Renal Function (Blood Urea Nitrogen/Serum Creatinine) After Treatment up to 90 Days After Randomization

Intervention	mg/dL (Mean)
	Discharge	30 days after discharge	60 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	8.38	1.72	1.85	2.50
IV Loop Diuretics (LD)	7.62	6.56	3.16	-3.78

SAFETY: Changes in Renal Function (Estimated Glomerular Filtration Rate) After Treatment up to 90 Days After Randomization

Intervention	mg/dL (Mean)
	Discharge	30 days after discharge	60 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	3.77	0.28	0.07	5.66
IV Loop Diuretics (LD)	3.03	1.65	1.97	1.72

SAFETY: Changes in Renal Function (Serum Creatinine) After Treatment up to 90 Days After Randomization

Intervention	mL/min/1.73m2 (Mean)
	Discharge	30 days after discharge	60 days after discharge	90 days after discharge
Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration	-2.31	-0.56	-2.49	5.70
IV Loop Diuretics (LD)	-2.68	-3.33	2.15	7.41

Article	Year
"Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review. Current vascular pharmacology, 2023, Volume: 21, Issue:2 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2023
Left ventricular remodeling and dysfunction in primary aldosteronism. Journal of human hypertension, 2021, Volume: 35, Issue:2 Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypertrophy, Left Ventricular; Ventricular Dy	2021
Blocking aldosterone in heart failure. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:5 Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure;	2009
Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2012, Volume: 60, Issue:5 Topics: Aldosterone; Angiotensin II; Animals; Heart Ventricles; Humans; Renal Insufficiency, Chronic; Ventri	2012
Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances. European journal of clinical investigation, 2012, Volume: 42, Issue:10 Topics: Aldosterone; Genetic Techniques; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Ant	2012
Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation, 2003, Oct-14, Volume: 108, Issue:15 Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal	2003
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Molecular and cellular endocrinology, 2004, Mar-31, Volume: 217, Issue:1-2 Topics: Aldosterone; Angiotensin Receptor Antagonists; Digoxin; Enzyme Inhibitors; Eplerenone; Female; Human	2004
Pathophysiology of heart failure following myocardial infarction. Heart (British Cardiac Society), 2005, Volume: 91 Suppl 2 Topics: Aldosterone; Angiotensins; Fibrosis; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardia	2005
Role of aldosterone blockade in heart failure. Heart failure clinics, 2005, Volume: 1, Issue:1 Topics: Aldosterone; Drug Evaluation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Recepto	2005
[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system]. Praxis, 1997, Feb-11, Volume: 86, Issue:7 Topics: Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Heart Failure; Humans;	1997

Article	Year
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. European journal of heart failure, 2017, Volume: 19, Issue:9 Topics: Aged; Aldosterone; Drug Monitoring; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Middl	2017
Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. Journal of cardiovascular pharmacology, 2009, Volume: 53, Issue:6 Topics: Administration, Oral; Aldosterone; Cross-Over Studies; Delayed-Action Preparations; Drug Administrat	2009
Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial. Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:11 Topics: Aged; Aldosterone; Anaerobic Threshold; Angiotensin II; Cardiac Output, Low; Cardiac Volume; Echocar	2009
Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. Journal of hypertension, 2011, Volume: 29, Issue:2 Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen	2011
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. European journal of heart failure, 2011, Volume: 13, Issue:12 Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Fem	2011
Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:5 Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiograp	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4 Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz	2003
Neurohumoral changes in patients with left ventricular dysfunction following acute myocardial infarction and the effect of nitrate therapy: a randomized, double-blind, placebo-controlled long-term study. Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:4 Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Double-Blind Method; Echocardiography; Female;	2006
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:9 Topics: Aged; Aldosterone; Biomarkers; Canrenone; Disease Progression; Double-Blind Method; Echocardiography	2007
The renin angiotensin aldosterone system and frusemide response in congestive heart failure. British journal of clinical pharmacology, 1995, Volume: 39, Issue:1 Topics: Administration, Oral; Aged; Aldosterone; Captopril; Cross-Over Studies; Drug Therapy, Combination; F	1995
[The changes of PRA, ATII, ald, ET and ANP in patients with left ventricular diastolic heart failure and intervention with enalapril]. Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 1997, Volume: 22, Issue:4 Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret	1997
Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:2 Topics: Adult; Aged; Aldosterone; Blood Pressure; Cyclic GMP; Drug Synergism; Humans; Male; Metabolic Cleara	1999
Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation, 2000, Jul-11, Volume: 102, Issue:2 Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Output; Cardiotonic Agents; Catecholamines; Ch	2000
Effects of perindopril on aldosterone production in the failing human heart. The American journal of cardiology, 2002, May-15, Volume: 89, Issue:10 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Catheterization; Female; Heart Failur	2002
Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. European journal of heart failure, 2002, Volume: 4, Issue:3 Topics: Aged; Aldosterone; Analysis of Variance; Atrial Fibrillation; Atrial Natriuretic Factor; Female; Hea	2002

Article	Year
Comparison of Echocardiographic Changes Between Surgery and Medication Treatment in Patients With Primary Aldosteronism. Journal of the American Heart Association, 2022, 07-05, Volume: 11, Issue:13 Topics: Aldosterone; Echocardiography; Humans; Hyperaldosteronism; Hypertension; Hypertrophy, Left Ventricul	2022
Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2023, Volume: 25, Issue:2 Topics: Aldosterone; Diastole; Echocardiography; Essential Hypertension; Female; Humans; Hypertension; Hyper	2023
Improvement of hypertension control and left-ventricular function after cure of primary hyperparathyroidism. Frontiers in endocrinology, 2023, Volume: 14 Topics: Adult; Aged; Aldosterone; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypercalcemia; Hype	2023
Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats. Endocrinology, 2017, 06-01, Volume: 158, Issue:6 Topics: Aldosterone; Animals; Gene Expression Regulation; Heart; Heart Diseases; Hyperaldosteronism; Hyperte	2017
Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. Journal of hypertension, 2018, Volume: 36, Issue:2 Topics: Adult; Aged; Aldosterone; Echocardiography; Essential Hypertension; Female; Heart; Humans; Hyperaldo	2018
Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovascular research, 2018, 02-01, Volume: 114, Issue:2 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotoxicity; Connective Tissue Gr	2018
Speckle-Tracking Echocardiographic Layer-Specific Strain Analysis on Subclinical Left Ventricular Dysfunction in Patients With Primary Aldosteronism. American journal of hypertension, 2019, 01-15, Volume: 32, Issue:2 Topics: Adult; Aged; Aldosterone; Asymptomatic Diseases; Biomarkers; Blood Pressure; Case-Control Studies; C	2019
Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:10 Topics: Adult; Aldosterone; Blood Pressure Monitoring, Ambulatory; Cross-Sectional Studies; Echocardiography	2013
Neuroendocrine and haemodynamic changes in single-lead atrial pacing and dual-chamber pacing modes. The Journal of international medical research, 2013, Volume: 41, Issue:4 Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Flow Velocity; Cross-Over Studie	2013
Synergic effect of high renin and aldosterone levels on inappropriate left ventricular mass and systolic function: a tissue Doppler study. International journal of cardiology, 2013, Oct-12, Volume: 168, Issue:5 Topics: Adult; Aldosterone; Biomarkers; Echocardiography, Doppler; Female; Humans; Hypertension; Male; Renin	2013
Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clinical biochemistry, 2014, Volume: 47, Issue:13-14 Topics: Adult; Aldosterone; Echocardiography; Essential Hypertension; Female; Humans; Hyperaldosteronism; Hy	2014
Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:6 Topics: Adult; Aldosterone; Analysis of Variance; Case-Control Studies; Chi-Square Distribution; Diastole; E	2015
Aldosterone and right ventricular dysfunction: more data to be collected with prospective cohort studies. Journal of cardiovascular medicine (Hagerstown, Md.), 2016, Volume: 17, Issue:1 Topics: Aldosterone; Cohort Studies; Heart Failure; Humans; Prospective Studies; Ventricular Dysfunction, Le	2016
Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. Circulation. Heart failure, 2016, Volume: 9, Issue:1 Topics: Adipocytes, Brown; Adipocytes, White; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Ani	2016
Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study. Circulation. Cardiovascular imaging, 2016, Volume: 9, Issue:6 Topics: Adult; Aged; Aldosterone; Biomarkers; Biomechanical Phenomena; Blood Pressure; Case-Control Studies;	2016
Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC. Heart failure, 2016, Volume: 4, Issue:10 Topics: Adult; Aged; Aldosterone; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Female; He	2016
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:2 Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Dopple	2008
Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovascular research, 2009, Feb-15, Volume: 81, Issue:3 Topics: Aldosterone; Animals; Cardiac Catheterization; Corticosterone; Cytochrome P-450 CYP11B2; Disease Mod	2009
Comparison of the effects of intrapericardial and intravenous aldosterone infusions on left ventricular fibrosis in rats. European journal of heart failure, 2008, Volume: 10, Issue:12 Topics: Aldosterone; Animals; Disease Models, Animal; Fibrosis; Heart Ventricles; Infusions, Intravenous; In	2008
Conventional therapy with an ACE inhibitor diminishes left ventricular dyssynchrony during the progression of heart failure. International journal of cardiology, 2010, Apr-01, Volume: 140, Issue:1 Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Comorbidity; Disease	2010
Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009, Volume: 23, Issue:7 Topics: Aldosterone; Animals; Capillaries; Coronary Vessels; Diabetes Complications; Diabetes Mellitus, Expe	2009
Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy. Cytokine, 2010, Volume: 49, Issue:3 Topics: Aldosterone; Biomarkers; Cardiomyopathy, Dilated; Coronary Circulation; Female; Humans; Inflammation	2010
Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology, 2010, Volume: 117, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Diastol	2010
Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice. Hypertension research : official journal of the Japanese Society of Hypertension, 2012, Volume: 35, Issue:3 Topics: Aldosterone; Animals; Apoptosis; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal;	2012
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. Journal of cardiac failure, 2012, Volume: 18, Issue:4 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho	2012
Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. American journal of physiology. Heart and circulatory physiology, 2012, Sep-01, Volume: 303, Issue:5 Topics: Aldosterone; Animals; Autophagy; Disease Models, Animal; Disease Progression; Fibrosis; Heart Failur	2012
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:11 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cardiovascular Agents;	2012
Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction. Cardiovascular research, 2013, Mar-01, Volume: 97, Issue:3 Topics: Aldosterone; Angiotensin III; Animals; Baroreflex; Blood Pressure; Brain; Disease Models, Animal; Di	2013
Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? Wiener klinische Wochenschrift, 2002, Mar-28, Volume: 114, Issue:5-6 Topics: Aged; Aldosterone; Creatinine; Female; Heart Failure; Humans; Leukocyte Count; Male; Middle Aged; Pr	2002
Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure. Heart and vessels, 2002, Volume: 17, Issue:2 Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Aldosterone; Angiotensin Receptor Antagonists; Angio	2002
Improved neurohormonal markers of ventricular function after restoring sinus rhythm by the Maze procedure. The Annals of thoracic surgery, 2003, Volume: 75, Issue:3 Topics: Adult; Aged; Aldosterone; Angiotensin II; Atrial Fibrillation; Atrial Natriuretic Factor; Chronic Di	2003
Aldosterone blockade and heart failure. The New England journal of medicine, 2003, Apr-03, Volume: 348, Issue:14 Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I	2003
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circulation research, 2003, Jul-11, Volume: 93, Issue:1 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis	2003
In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern. Journal of cardiac failure, 2003, Volume: 9, Issue:4 Topics: Adult; Aged; Aldosterone; Area Under Curve; Biomarkers; Blood Pressure; Cardiomyopathies; Diastole;	2003
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. MMW Fortschritte der Medizin, 2003, Nov-20, Volume: 145, Issue:47 Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid	2003
Diuretic use, progressive heart failure, and death in patients in SOLVD. Journal of the American College of Cardiology, 2004, May-05, Volume: 43, Issue:9 Topics: Aldosterone; Cause of Death; Diuretics; Heart Failure; Humans; Potassium; Stroke Volume; Ventricular	2004
Furosemide and the progression of left ventricular dysfunction in experimental heart failure. Journal of the American College of Cardiology, 2004, Sep-15, Volume: 44, Issue:6 Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Biomarkers; Disease Models, Animal; Disease Progress	2004
Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. Journal of the American College of Cardiology, 2004, Sep-15, Volume: 44, Issue:6 Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Diuretics; Electrolytes; Furosemide; Heart Failure;	2004
Adrenocorticotropic hormone is produced in the ventricle of patients with essential hypertension. Journal of hypertension, 2005, Volume: 23, Issue:2 Topics: Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Aorta; Cardiac Catheterization; Case-Control	2005
Ischemic etiology of heart failure identifies patients with more severely impaired exercise capacity. International journal of cardiology, 2005, Oct-10, Volume: 104, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Blood Flow Velocity; Blood Pressure; Echocardiography;	2005
Increased plasma aldosterone-to-renin ratio is associated with impaired left ventricular longitudinal functional reserve in patients with uncomplicated hypertension. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2008, Volume: 21, Issue:3 Topics: Aldosterone; Exercise Test; Female; Fractional Flow Reserve, Myocardial; Humans; Hypertension; Male;	2008
Progressive diastolic dysfunction in the female mRen(2). Lewis rat: influence of salt and ovarian hormones. The journals of gerontology. Series A, Biological sciences and medical sciences, 2008, Volume: 63, Issue:1 Topics: Aldosterone; Animals; Blood Pressure; Diastole; Estrogens; Female; Heart Failure, Diastolic; Mice; O	2008
A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. The Journal of clinical investigation, 1995, Volume: 95, Issue:3 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic GMP; Disease Models, Animal; Dogs; Heart Atr	1995
Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure. International journal of cardiology, 1995, Volume: 51, Issue:3 Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Disease Progression; Endothe	1995
Left ventricular systolic function in primary aldosteronism and hypertension. Journal of hypertension, 1998, Volume: 16, Issue:12 Pt 2 Topics: Adult; Aldosterone; Echocardiography, Doppler; Female; Humans; Hyperaldosteronism; Hypertension; Hyp	1998
Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. American heart journal, 1999, Volume: 137, Issue:4 Pt 1 Topics: Aldosterone; Angiotensinogen; Asian People; Atrial Natriuretic Factor; Cohort Studies; Female; Gene	1999
Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. American journal of physiology. Heart and circulatory physiology, 2000, Volume: 278, Issue:3 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Coronary Vessels; Disease Models, Animal; Endotheli	2000
Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. European journal of heart failure, 2001, Volume: 3, Issue:6 Topics: Aged; Aldosterone; Arginine Vasopressin; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Endo	2001
Left ventricular structure and diastolic function in subjects with two hypertensive parents. Blood pressure, 2001, Volume: 10, Issue:4 Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Blood Pressure; Case-Control Studies; Catecholamines	2001

aldosterone and Left Ventricular Dysfunction